Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Common Stock Issued
Cash raised by issuing new shares.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued outflow grows to $33.57M
Q1 FY2026 common stock issued was $33.57M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $163.72M. Over 3 fiscal years it compounded at -38.5% a year.
Context
- Common stock issued amounted to 194.3% of revenue in FY2025, down 111.3 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near $33.57M or moves back toward the trailing-twelve-month quarterly average of $40.93M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 131.49M USD
- Year-over-year change
- -25.7%
- 4-year CAGR
- -34.0%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 131.49M | -25.7% |
| FY2024 | 2024-12-31 | 176.9M | +47.7% |
| FY2023 | 2023-12-31 | 119.8M | -78.8% |
| FY2022 | 2022-12-31 | 565.79M | -18.4% |
| FY2021 | 2021-12-31 | 693.57M | — |
Common Stock Issued vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 common stock issued of $163.72M is the largest of the 10 companies compared; the peer median is $14.62M.
- Its year-over-year change of +37.7% is the 3rd highest of 10, against a peer median of -61.7%.
- Common stock issued amounts to 247.7% of revenue for NTLA, versus a peer median of 67.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $163.72M | +37.7% | -38.5% | 247.7% | |
| LTM Mar 2026 | $127.76M | +172.2% | +197.3% | — | |
| LTM Sep 2026 | $116.41M | -61.7% | +660.1% | 462.5% | |
| LTM Mar 2026 | $80.12M | -196.8% | +547.3% | 442.8% | |
| LTM Mar 2026 | $41.66M | -27.3% | +223.2% | 107.7% | |
| LTM Mar 2026 | $24.86M | -60.1% | -15.0% | 31.2% | |
| LTM Jun 2026 | $14.62M | -96.9% | +64.1% | 9.4% | |
| LTM Mar 2026 | $7.51M | +73.4% | +31.2% | 67.0% | |
| LTM Jun 2026 | $2.55M | -91.7% | — | 3.0% | |
| LTM Mar 2026 | $215K | -99.9% | — | — | |
| Peer median (excluding NTLA) | $14.62M | -61.7% | +197.3% | 67.0% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (519.02M) |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 10.29M |
| Deferred Income Tax | 8.93M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 47.01M | 91.4M | 134.05M | 154.27M | 154.27M |
| Change in Working Capital | (22.9M) | (53.87M) | (52.45M) | 11.88M | (73.75M) |
| Accounts Receivables | 99K | (1.74M) | (32.69M) | 27.94M | (951K) |
| Inventory | 7.82M | 0 | 0 | 0 | 0 |
| Accounts Payables | 529K | (4.58M) | 2.52M | 6.8M | 5.99M |
| Other Working Capital | (31.36M) | (47.55M) | (22.29M) | (22.86M) | (78.79M) |
| Other Non-Cash Items | 2.94M | 95.8M | (3.47M) | (6.3M) | 79.34M |
| Operating Cash Flow | (225.03M) | (333.29M) | (394.09M) | (348.88M) | (348.88M) |
| Capital Expenditures | (12.76M) | (58.39M) | (13.99M) | (5.78M) | (5.78M) |
| Acquisitions (Net) | (3M) | (44.68M) | 0 | 0 | 0 |
| Purchases of Investments | (1.02B) | (429.03M) | (904.46M) | (935.57M) | (935.57M) |
| Sales of Investments | 485.6M | 647.58M | 887.1M | 1.07B | 1.05B |
| Other Investing Activities | 0 | 44.83M | 0 | 0 | 20.97M |
| Investing Cash Flow | (550.78M) | 160.31M | (31.35M) | 125.57M | 125.57M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 693.57M | 565.79M | 119.8M | 176.9M | 131.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.12M | 17.17M | 10.53M | 8.85M | 54.26M |
| Financing Cash Flow | 736.69M | 582.96M | 130.32M | 185.75M | 185.75M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (39.12M) | 409.98M | (295.11M) | (37.57M) | (37.57M) |
| Free Cash Flow | (237.79M) | (391.68M) | (408.07M) | (354.66M) | (354.66M) |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.